These prodrug nanovesicles have a sheddable polyethylene glycol shell layer and CRGDK ligands, which remain stable during circulation while exposing targeting ligands in tumors, significantly inhibiting autophagy and inducing MHC-I expression, increasing tumor antigen presentation, recruiting more tumor-infiltrating T lymphocytes, and suppressing IFN-γ-induced intratumoral PD-L1 expression. The gene discussed is IFNG; the disease is neoplasm.